Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts
- PMID: 11880187
- DOI: 10.1016/s0304-3835(01)00866-7
Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts
Abstract
Previously, we demonstrated the significance of vascular endothelial growth factor (VEGF) in promoting the growth of tetracycline-regulated human VEGF165 retroviral vector transduced T47-D breast carcinoma cells, particularly at the early stages of tumor development (Cancer Res. 57 (1997) 3924). Here, we showed histologically that the VEGF overexpressing (VEGF (+)) T47-D cells formed a distinct tumor nodule at day 11, while control cells showed no evidence of replication. The VEGF (+) tumors contained large avascular cavities at days 11 and 21, which were replaced by basement membrane-lined channels at day 30. The number of proliferating tumor cells was not significantly different between the VEGF (+) and control tumors, but the number of apoptotic cells was significantly decreased in the VEGF (+) tumors. Increased nitric oxide synthase (NOS) activity was also observed in the VEGF (+) tumors. These findings indicate that VEGF contributes to tumor growth through inhibition of apoptosis and increased NOS activity, which may be critical during pre-vascular stages of tumor development.
Similar articles
-
p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells.Nat Med. 1998 Dec;4(12):1371-6. doi: 10.1038/3957. Nat Med. 1998. PMID: 9846573
-
Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production.Cancer Res. 2001 Apr 1;61(7):3182-7. Cancer Res. 2001. PMID: 11306506
-
Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system.Leukemia. 2001 Sep;15(9):1433-41. doi: 10.1038/sj.leu.2402217. Leukemia. 2001. PMID: 11516104
-
Role of nitric oxide in growth of solid tumours: a balancing act.Essays Biochem. 1997;32:61-72. Essays Biochem. 1997. PMID: 9493011 Review.
-
Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to human disease.Microcirculation. 2005 Jan-Feb;12(1):129-140. doi: 10.1080/10739680590896081. Microcirculation. 2005. PMID: 15825252 Review.
Cited by
-
Correlation of genetic polymorphism of vascular endothelial growth factor gene with susceptibility to lung cancer.Cancer Gene Ther. 2015 Jun;22(6):312-6. doi: 10.1038/cgt.2015.24. Epub 2015 Jun 12. Cancer Gene Ther. 2015. PMID: 26065377
-
Role of connexins in infantile hemangiomas.Front Pharmacol. 2013 Apr 16;4:41. doi: 10.3389/fphar.2013.00041. eCollection 2013. Front Pharmacol. 2013. PMID: 23596415 Free PMC article.
-
Prognostic significance of three endothelial nitric oxide synthase (eNOS) polymorphisms and metabolic syndrome (MetS) in patients with colorectal cancer.Genes Genomics. 2022 Jun;44(6):659-670. doi: 10.1007/s13258-022-01246-9. Epub 2022 Apr 4. Genes Genomics. 2022. PMID: 35377131
-
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.Am J Pathol. 2002 Dec;161(6):2295-309. doi: 10.1016/s0002-9440(10)64505-1. Am J Pathol. 2002. PMID: 12466143 Free PMC article.
-
Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients.Tumour Biol. 2014 Jul;35(7):6501-9. doi: 10.1007/s13277-014-1858-4. Epub 2014 Apr 1. Tumour Biol. 2014. PMID: 24687551
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical